Teleflex Incorporated (NYSE:TFX) Receives $182.63 Consensus PT from Analysts

Teleflex Incorporated (NYSE:TFX) has been given a consensus rating of “Hold” by the eleven research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $182.63.

A number of analysts recently commented on the stock. Royal Bank of Canada downgraded shares of Teleflex from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $220.00 to $155.00 in a report on Friday, February 28th. Piper Sandler reiterated a “neutral” rating and set a $140.00 price objective (down previously from $255.00) on shares of Teleflex in a research report on Friday, February 28th. Citizens Jmp lowered Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. Wells Fargo & Company cut their target price on Teleflex from $214.00 to $146.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Finally, StockNews.com lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, February 28th.

Institutional Trading of Teleflex

Large investors have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB grew its stake in shares of Teleflex by 103.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 100 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Teleflex during the fourth quarter worth about $29,000. True Wealth Design LLC increased its stake in Teleflex by 62.3% during the fourth quarter. True Wealth Design LLC now owns 271 shares of the medical technology company’s stock valued at $48,000 after acquiring an additional 104 shares during the period. Avior Wealth Management LLC raised its holdings in Teleflex by 81.2% in the 4th quarter. Avior Wealth Management LLC now owns 279 shares of the medical technology company’s stock valued at $50,000 after acquiring an additional 125 shares in the last quarter. Finally, IFP Advisors Inc lifted its position in shares of Teleflex by 238.5% in the 4th quarter. IFP Advisors Inc now owns 308 shares of the medical technology company’s stock worth $55,000 after acquiring an additional 217 shares during the period. 95.62% of the stock is owned by institutional investors.

Teleflex Price Performance

Shares of NYSE:TFX opened at $131.93 on Friday. The firm’s 50 day moving average is $154.86 and its two-hundred day moving average is $186.26. The firm has a market capitalization of $6.12 billion, a P/E ratio of 26.23, a PEG ratio of 1.73 and a beta of 1.19. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37. Teleflex has a 52 week low of $128.55 and a 52 week high of $249.91.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 earnings per share for the quarter, topping the consensus estimate of $3.86 by $0.03. The business had revenue of $795.40 million during the quarter, compared to the consensus estimate of $813.24 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. Analysts anticipate that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 17th. Shareholders of record on Friday, March 7th were given a $0.34 dividend. The ex-dividend date was Friday, March 7th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.03%. Teleflex’s dividend payout ratio is currently 95.77%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.